ALIMEMAZINE TARTRATE

Kraj: Irlandia

Język: angielski

Źródło: HPRA (Health Products Regulatory Authority)

Składnik aktywny:

ALIMEMAZINE TARTRATE

Dostępny od:

Mercury Pharmaceuticals (Ireland) Ltd

Kod ATC:

R06AD01

INN (International Nazwa):

ALIMEMAZINE TARTRATE

Dawkowanie:

10 Milligram

Forma farmaceutyczna:

Film Coated Tablet

Typ recepty:

Product subject to prescription which may be renewed (B)

Dziedzina terapeutyczna:

alimemazine

Status autoryzacji:

Not Marketed

Data autoryzacji:

2015-01-23

Charakterystyka produktu

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Alimemazine tartrate 10mg Film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 10mg of alimemazine tartrate.
Also contains lactose.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablets
Dark blue, circular, biconvex and film coated tablet. One side of
tablet is marked with AL and other side is plain.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Alimemazine has powerful antihistamine and anti-emetic actions and is
used in the management of urticaria and
pruritus.
Alimemazine may be used in pre-medication as a sedative before
anaesthesia in children aged between 2 to 7 years.
The alimemazine syrup formulation is suitable for these indications in
children.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For oral use.
Not recommended for infants less than 2 years old.
Do NOT exceed the recommended dose (see also section 4.9).
_Urticaria and pruritus_
Adults: 10mg two or three times daily.
Elderly: Dosage should be reduced to 10mg once or twice daily.
Children over 2 years of age: The use of Alimemazine Syrup is
recommended.
_As a sedative before anaesthesia_
The use of Alimemazine Syrup is recommended.
4.3 CONTRAINDICATIONS
Use in patients with hepatic or renal dysfunction, epilepsy,
Parkinson's disease, hypothyroidism, phaeochromocytoma,
myasthenia gravis, and prostatic hypertrophy.
Use in patients known to be hypersensitive to phenothiazines or to any
of the excipients listed in section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___